Acadia shares jumped 7% after the CHMP backed Daybu for EU approval in Rett syndrome, a key regulatory step ahead of a final European Commission decision in the coming months. The opinion materially improves the odds of approval for the drug and supports the company’s commercial outlook. The move is likely to be stock-specific rather than sector-wide.
Acadia shares jumped 7% after the CHMP backed Daybu for EU approval in Rett syndrome, a key regulatory step ahead of a final European Commission decision in the coming months. The opinion materially improves the odds of approval for the drug and supports the company’s commercial outlook. The move is likely to be stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
